If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
137
results.
Updated on
12/11/2025 [06:57:00]
Absstract of: WO2025231209A1
A computing system, a computer implemented method, and a wearable computing device to predict insulin resistance in a wearer of the wearable computing device without requiring additional invasive testing other than test data that may already be available, although not required, is provided. For instance, a machine-learned model is trained to predict insulin resistance in the wearer of the wearable computing device based at least in part on non-invasive biometric data associated with the wearer. Then, one or more non-transitory computer-readable media cause the computing system to perform operations via one or more processors. The operations include receiving the non-invasive biometric data from one or more sensors associated with the wearable computing device; and implementing the machine-learned model to determine if the non-invasive biometric data associated with the wearer is indicative of insulin resistance.
Absstract of: US2025339612A1
The present disclosure relates to a self-lubricating cannula for use in delivering a fluid medication to a subcutaneous site. The self-lubricating cannula comprises polyether block polyamide and an additive configured to facilitate the manufacture of a tipped self-lubricating cannula. The present disclosure also provides a method of making a self-lubricating cannula and a method of administering insulin using a self-lubricating cannula.
Absstract of: US2025342932A1
Dose guidance systems and methods for titrating medication doses are described. The dose guidance system may receive glucose data from a continuous glucose monitor and may receive medication data related to medication administered by the user. The dose guidance system may initialize dose guidance parameters, recommend medication doses, titrate medication doses, and provide alerts based on the glucose data and medication data.
Absstract of: US2025341624A1
A system for millimeter RADAR object recognition and classification using sub-band frequency interference and resonance effects from primary targets signals and reflected signals from secondary target preferably in the form of Wideband Chaos Generating Material (WCGM) objects, preferably detecting frequency dependent absorbing material, frequency dependent resonance effects from the second and primary target objects, frequency signal resonance effects caused by water molecule dipole effects in different sugar solutions, impedance of material, shape of metamaterial, and interference effects due to combination of signal sources resulting in a wider range of transmitter and scanning frequency band for RADAR based interrogation of target objects. The RADAR system makes opportunistic use of traditionally seen problematic interference signals, as extra signal sources providing extended range and frequency bandwidth for frequency-based interrogation of target object signatures in a frequency-intensity plane, a frequency-polarization plane, and a frequency-phase shift plane for doppler effects.
Absstract of: US2025339033A1
Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from the palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0.9216 when compared to a standard electrochemical glucose analysis test.
Absstract of: US2025339060A1
Devices, systems and methods for blood glucose monitoring. The device includes a light emitter, configured to emit light signals; a light receiver, configured to receive the reflected light signal; a controller, configured to operatively connect with the light emitter and the light receiver; and an enclosure. The light signal comprises a first light signal having a first wavelength of about 940 nm, a second light signal having a second wavelength of about 1350 nm, and/or a third light signal having a third wavelength of about 1500 nm, wherein the controller comprises an operating module, and further comprises or operatively connects with a data processing system comprising a machine learning module that analyzes the data signal to generate an output data. The devices, systems and methods are non-invasive and monitor blood glucose levels in real time with high accuracy.
Absstract of: US2025339617A1
Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles.
Absstract of: US2025339618A1
A system for monitoring autonomic nervous system (ANS) function in a subject includes at least one sensor configured to acquire a first physiological signal related to heart activity of the subject, one or more additional sensors configured to acquire one or more physiological signals, a processing unit configured to receive, process and analyze the first and additional physiological signals to monitor/detect, in real time, at least one of an autonomic nervous system dysfunction and a change in a physiological state of the subject and determine an output condition based on the detection, and an output mechanism configured to perform, based on the output condition, generating an alert, initiating a treatment, and/or storing data. At least one of the additional sensors is a blood glucose sensor, a respiration sensor, a sudomotor activity sensor, a pulse wave sensor, an electroencephalography (EEG) sensor, an electromyography (EMG) sensor or a motion sensor.
Absstract of: US2025339338A1
A blood storage container along with an aqueous composition for the storage of packed red blood cells is described. In a preferred embodiment, the container is not made of DEHP plasticizer. In some embodiments, the container is made from a polymeric material and a non-DEHP plasticizer. In some embodiments, the aqueous composition is made of about 1 to about 3 mM adenine, about 20 to about 115 mM dextrose, about 15 to about 60 unmetabolizable membrane-protectant sugar, about 20 to about 30 mM sodium bicarbonate, and about 4 to about 20 mM disodium phosphate. In a most preferred embodiment, the DEHP-lacking container is made from a PVC polymeric material and a DINCH plasticizer and the aqueous composition is made of about 2 mM adenine, about 80 mM dextrose, 55 mM unmetabolizable membrane-protectant sugar, about 26 mM sodium bicarbonate, and about 12 mM disodium phosphate.
Absstract of: US2025339064A1
A diagnostic Electrochemical Impedance Spectroscopy (EIS) procedure is applied to measure values of impedance-related parameters for one or more sensing electrodes. The parameters may include real impedance, imaginary impedance, impedance magnitude, and/or phase angle. The measured values of the impedance-related parameters are then used in performing sensor diagnostics, calculating a highly-reliable fused sensor glucose value based on signals from a plurality of redundant sensing electrodes, calibrating sensors, detecting interferents within close proximity of one or more sensing electrodes, and testing surface area characteristics of electroplated electrodes. Advantageously, impedance-related parameters can be defined that are substantially glucose-independent over specific ranges of frequencies. An Application Specific Integrated Circuit (ASIC) enables implementation of the EIS-based diagnostics, fusion algorithms, and other processes based on measurement of EIS-based parameters.
Absstract of: AU2025252653A1
Abstract The present disclosure relates to a sterile medical product for parenteral nutrition comprising a polymeric container having at least a first and a second chamber which are sep- arated by a non-permanent peel seal, wherein the first chamber contains a composition of amino acids and optional- ly electrolytes, and wherein the second chamber contains a dextrose solution, and wherein the product is characterized by a high protein (nitrogen) content per volume. The recon- stituted solution is configured to be administered periph- erally or centrally for the treatment of patients suffering from malnutrition and/or having a need for increased uptake of amino acids. Abstract The present disclosure relates to a sterile medical product for parenteral nutrition comprising a polymeric container having at least a first and a second chamber which are sep- arated by a non-permanent peel seal, wherein the first chamber contains a composition of amino acids and optional- ly electrolytes, and wherein the second chamber contains a dextrose solution, and wherein the product is characterized by a high protein (nitrogen) content per volume. The recon- stituted solution is configured to be administered periph- erally or centrally for the treatment of patients suffering from malnutrition and/or having a need for increased uptake of amino acids. ct b s t r a c t c t h e p r e s e n t d i s c l o s u r e r e l a t e s t o a s t e r i l e m e d i c a l p r o d u c t f o r p a r e n t e r a l n
Absstract of: US2025339611A1
The present disclosure relates to the use of a PFAS-free cannula in delivering a fluid medication, such as insulin, to a subcutaneous site. The cannula comprises polycarbonate polyurethane polysiloxane (PC-PU-PS), wherein the cannula is configured for subcutaneous insertion into the tissue of the individual in need thereof. The disclosure includes methods for administering insulin using the cannula and infusion devices comprising the cannula.
Absstract of: EP4643774A1
Provided is an implant apparatus for a continuous glucose monitor. The implant apparatus includes a housing assembly and a driving assembly disposed in the housing assembly. The housing assembly includes an outer housing. The outer housing has an opening at an end of the outer housing. The driving assembly has a locked state in which the driving assembly is fixed relative to the outer housing and a triggered state in which the driving assembly is movable towards the opening. The implant apparatus further includes a trigger. The outer housing includes a guiding channel located at a side wall of the outer housing and extending towards the opening. The trigger is movable along the guiding channel towards the opening and has a first position and a second position relative to the outer housing, to enable the driving assembly to switch from the locked state to the triggered state. A triggering direction of the trigger is oriented towards the opening, while a direction of a force applied by fingers of a user when the user holds the outer housing is oriented inwards in a radial direction of the outer housing. Force application directions of the two actions are perpendicular to each other. As a result, a probability of the user accidentally triggering the trigger when holding the outer housing is reduced, which reduces a risk of accidental triggering of the implant apparatus, improving use experience.
Absstract of: AU2023415722A1
Certain aspects of the present disclosure relate to a monitoring system comprising a continuous analyte sensor configured to generate analyte measurements associated with analyte levels of a patient, and a sensor electronics module coupled to the continuous analyte sensor and configured to receive and process the analyte measurements.
Absstract of: EP4643911A1
The present disclosure relates to the use of a PFAS-free cannula in delivering a fluid medication, such as insulin, to a subcutaneous site. The cannula comprises polycarbonate polyurethane polysiloxane (PC-PU-PS), wherein the cannula is configured for subcutaneous insertion into the tissue of the individual in need thereof. The disclosure includes methods for administering insulin using the cannula and infusion devices comprising the cannula.
Absstract of: EP4643910A1
The present disclosure relates to a self-lubricating cannula for use in delivering a fluid medication to a subcutaneous site. The self-lubricating cannula comprises polyether block polyamide and an additive configured to facilitate the manufacture of a tipped self-lubricating cannula. The present disclosure also provides a method of making a self-lubricating cannula and a method of administering insulin using a self-lubricating cannula.
Absstract of: EP4643777A1
Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.
Absstract of: WO2024211880A2
A method of therapy escalation for patients with diabetes includes receiving glucose data of a user from an in vivo glucose monitoring device, receiving first therapy information of a first therapy, wherein the first therapy includes basal insulin, calculating one or more glucose metrics based on the received glucose data, titrating a dose of the basal insulin based on the one or more glucose metrics, and determining overbasalization based on one or more of the glucose data and the first therapy information. Advantageously the system can regularly monitor glucose control of a user, detect overbasalization, provide frequent therapy intervention and adjustment, decrease a duration of intervention, and increase user adherence, outcomes, and satisfaction.
Absstract of: WO2025226760A1
Certain aspects of the present disclosure provide a monitoring system comprising one or more memories comprising executable instructions and one or more processors in data communication with the one or more memories and configured to execute the executable instructions to calculate a first reabsorption threshold based on glucose measurements and 1,5-AG measurements of a patient over a first period of time and calculate a second reabsorption threshold based on the glucose measurements and the 1,5-AG measurements of the patient over a second period of time. The one or more processors are further configured to detect a change of the second reabsorption threshold relative to the first reabsorption threshold; determine whether the change of the second reabsorption threshold relative to the first reabsorption threshold is an increase or a decrease; and provide therapy management guidance to the patient based on the increase or the decrease.
Absstract of: WO2025222911A1
A processing method and apparatus for a PPG signal-based blood glucose prediction model. The processing method for a PPG signal-based blood glucose prediction model comprises: constructing a PPG signal-based blood glucose prediction model and recording same as a first prediction model; constructing a first original data set by means of data acquisition; performing data preprocessing on the first original data set to obtain a first training data set; performing model training on the first prediction model on the basis of the first training data set; and when the training is finished, performing blood glucose prediction for an arbitrary subject on the basis of the first prediction model. The present invention can improve user experience and enhance user's motivation for self-monitoring.
Absstract of: US2025338210A1
Systems and methods for processing, transmitting and displaying data received from an analyte sensor, such as a glucose sensor, are provided. The data can be displayed on a hand-held display device having a display such as a key fob device including a user interface, such as an LCD and one or more buttons allows a user to view data, and a physical connector, such as USB port.
Absstract of: US2025334537A1
A method of manufacturing a working wire for a continuous glucose monitoring sensor includes receiving a substrate in a wound configuration. The substrate consists of a cobalt-chromium (Co—Cr) alloy. The substrate is unwound from the wound configuration. The substrate is allowed to naturally transition to a straight, linear configuration. A platinum layer is formed on the substrate. A membrane layer comprising a biological membrane is applied over the platinum layer. The working wire is formed to have a diameter in a range from 0.0025 inches to 0.005 inches. A working wire for a continuous glucose monitoring sensor includes a substrate consisting of a cobalt-chromium (Co—Cr) alloy, a platinum layer disposed on the substrate and a membrane layer comprising a biological membrane disposed over the platinum layer. A diameter of the working wire is in a range from 0.0025 inches to 0.005 inches.
Absstract of: US2025331741A1
A system includes an implantable medical device configured to measure blood-glucose concentration based on cardiac activity. The system further includes processing circuitry configured to generate, based on the plurality of periods, a plurality of waveforms representative of the blood-glucose concentration. The processing circuitry is further configured to identify at least one clinically significant feature that is present in each waveform. The processing circuitry is further configured to modify one or more of the plurality of waveforms such that the at least one feature is temporally aligned across the plurality of waveforms.
Absstract of: US2025331743A1
Techniques disclosed herein relate to adjustable glucose sensor initialization sequences. In some embodiments, the techniques may involve determining an initial amplitude of one or more voltage pulses of a sequence of voltage pulses applied to a working electrode of the glucose sensor that is at least partially inserted subcutaneously in a patient. The techniques may further involve determining a slope of one or more parameters of the glucose sensor. The techniques may further involve determining an updated amplitude of the one or more voltage pulses based on the slope of the one or more parameters. The techniques may further involve executing an initialization sequence using the one or more voltage pulses having the updated amplitude to the working electrode of the glucose sensor.
Nº publicación: US2025331738A1 30/10/2025
Applicant:
PHC HOLDINGS CORP [JP]
PHC Holdings Corporation
Absstract of: US2025331738A1
A blood glucose meter (10) comprises a main body part (11), a sensor mounting part (13), a measurement unit (14), a battery compartment (11a), a battery cover (12), a hinge (21), a lock pin (21a), and sliding surfaces (SL1, SL2). The battery cover (12) has an opening (12a) into which a jig Z is inserted during removal from the body portion (11). The hinge (21) deforms when pressed by the jig (Z) inserted through the opening (12a). The lock pin (21a) is provided at a position where it is exposed to the outside through the opening (12a), and when pressed by the jig (Z), the battery cover (12) is unlatched from the main body portion (11). When the battery cover (12) is slid along the sliding surfaces (SL1 and SL2) in a state in which the battery cover (12) is latched to the main body portion (11) by the lock pin (21a), a force in a compression direction is exerted on the hinge (21).
BOPI
Electronic site
